Can a second wave of new variant of the CJD be discarded in absence of observation of clinical non Met-Met cases?

Revue d'Epidemiologie et de Sante Publique

Volumn 54, Issue 2, 2006, Pages 111-115

  Valleron, A J ^a   Boelle, P Y ^a   Chatignoux, E ^a   Cesbron, J Y ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

Epidemiological predictions; Incubation period; Models; New variant of Creutzfeldt Jakob disease

Indexed keywords

ARTICLE; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; INCUBATION TIME; INFECTION RISK; MATHEMATICAL MODEL; UNITED KINGDOM;

EID: 33646703778     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0398-7620(06)76704-9     Document Type: Article

References (11)

1. Cousens SN, Vynnycky E, Zeidler M, Will RG, Smith PG. Predicting the CJD epidemic in humans. Nature 1997; 385: 197-8.
2. Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vCJD mortality in Great Britain. Nature 2000; 406: 583-4.
3. Huillard d'Aignaux JN, Cousens SN, Smith PG. Predictability of the UK variant Creutzfeldt-Jakob disease epidemic. Science 2001; 294: 1729-31.
4. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001; 294: 1726-8.
5. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
6. Huillard d'Aignaux J, Costagliola D, Maccario J, Billette de Villemeur T, Brandel JP, Deslys JP, et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53: 1197-201.
7. Lee HS, Brown P, Cervenakova L, Garruto RM, Alpers MP, Gajdusek DC, et al. Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. J Infect Dis 2001; 183: 192-6.
8. Boelle PY, Cesbron JY, Valleron AJ. Epidemiological evidence of higher susceptibility to vCJD in the young. BMC Infect Dis 2004; 4: 26.
9. Boelle PY, Thomas G, Valleron AJ, Cesbron JY, Will R. Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: updated, detailed analysis. Stat Methods Med Res 2003; 12: 221-33.
10. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-9.
11. Clarke P, Ghani A. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface 2005; 2: 19-31.